KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Depreciation & Amortization (2016 - 2025)

Alnylam Pharmaceuticals filings provide 15 years of Accumulated Depreciation & Amortization readings, the most recent being $322.7 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 19.36% to $322.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $322.7 million through Dec 2025, up 19.36% year-over-year, with the annual reading at $322.7 million for FY2025, 19.36% up from the prior year.
  • Accumulated Depreciation & Amortization hit $322.7 million in Q4 2025 for Alnylam Pharmaceuticals, up from $270.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $322.7 million in Q4 2025 and bottomed at $140.4 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $226.0 million, with a median of $223.1 million recorded in 2023.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 34.57% in 2021 before it increased 19.36% in 2025.
  • Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization stood at $140.4 million in 2021, then rose by 23.53% to $173.4 million in 2022, then increased by 28.61% to $223.1 million in 2023, then grew by 21.2% to $270.4 million in 2024, then grew by 19.36% to $322.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Accumulated Depreciation & Amortization are $322.7 million (Q4 2025), $270.4 million (Q4 2024), and $223.1 million (Q4 2023).